Provided by Tiger Trade Technology Pte. Ltd.

Regenxbio

10.72
-0.3400-3.07%
Post-market: 10.70-0.0200-0.19%19:30 EDT
Volume:1.01M
Turnover:10.87M
Market Cap:707.66M
PE:-2.85
High:11.16
Open:11.14
Low:10.49
Close:11.06
52wk High:16.19
52wk Low:5.46
Shares:66.01M
Float Shares:57.34M
Volume Ratio:1.11
T/O Rate:1.76%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.7652
EPS(LYR):-3.7593
ROE:-137.63%
ROA:-21.20%
PB:9.86
PE(LYR):-2.85

Loading ...

Regenxbio price target lowered to $30 from $32 at H.C. Wainwright

TIPRANKS
·
Mar 09

RegenXbio Faces FDA Clinical Holds: Heightened Development Risk, Potential Delays, and Investor Uncertainty

TIPRANKS
·
Mar 07

REGENXBIO Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Mar 07

Analysts Offer Insights on Healthcare Companies: RegenXBio (RGNX) and Kura Oncology (KURA)

TIPRANKS
·
Mar 06

Regenxbio price target lowered to $17 from $18 at Morgan Stanley

TIPRANKS
·
Mar 06

Regenxbio price target lowered to $42 from $45 at Stifel

TIPRANKS
·
Mar 06

BUZZ-Regenxbio falls as Q4 loss widens

Reuters
·
Mar 06

Regenxbio Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 05

Regenxbio Q4 revenue rises but loss widens as costs increase

Reuters
·
Mar 05

Regenxbio Q4 R&D expenses rise 18.3% to USD 59.6 million

Reuters
·
Mar 05

BRIEF-Regenxbio Q4 License & Royalty Revenue USD 27.148 Million

Reuters
·
Mar 05

Regenxbio Q4 Operating Expenses USD 87.973 Million

THOMSON REUTERS
·
Mar 05

Regenxbio Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

THOMSON REUTERS
·
Mar 05

REGENXBIO to Present RGX-202 Duchenne Gene Therapy Data at MDA Clinical and Scientific Conference

Reuters
·
Mar 04

Rosen Law Firm Urges Regenxbio Investors to Meet April 14 Lead Plaintiff Deadline in Securities Class Action

Reuters
·
Mar 04

Regenxbio Inc expected to post a loss of 96 cents a share - Earnings Preview

Reuters
·
Mar 03

MAHA Is Bringing Chaos to Biotech Investment Beyond Just Vaccines -- Heard on the Street -- WSJ

Dow Jones
·
Mar 03

LEVI & KORSINSKY, LLP: RGNX DISCLOSURE TIMELINE REVEALS PATTERN OF ALLEGED INVESTOR HARM

TIPRANKS
·
Mar 03

When a Clinical Hold Disrupts a Gene Therapy Program: What Happened to Regenxbio Stock

TIPRANKS
·
Mar 03

REGENXBIO to Participate in Upcoming Investor Conferences

Reuters
·
Mar 02